Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Taiwan · Delayed Price · Currency is TWD

71.90

-1.10 (-1.51%)

Nov 6, 2026, 1:33 PM CST

Market Cap	11.33B -5.9%
Revenue (ttm)	471.13M +6.4%
Net Income	22.50M
EPS	0.14
Shares Out	157.54M
PE Ratio	499.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,671
Open	70.00
Previous Close	73.00
Day's Range	67.30 - 71.90
52-Week Range	67.30 - 93.70
Beta	0.61
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2013

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6576

Full Company Profile

Financial Performance

In 2025, Foresee Pharmaceuticals's revenue was 431.27 million, an increase of 3.01% compared to the previous year's 418.69 million. Losses were -883.15 million, -18.31% less than in 2024.

Financial Statements